Zobrazeno 1 - 10
of 368
pro vyhledávání: '"Herbert, Hurwitz"'
Autor:
Jun Yin, Shaheenah Dawood, Romain Cohen, Jeff Meyers, John Zalcberg, Takayuki Yoshino, Matthew Seymour, Tim Maughan, Leonard Saltz, Eric Van Cutsem, Alan Venook, Hans-Joachim Schmoll, Richard Goldberg, Paulo Hoff, J. Randolph Hecht, Herbert Hurwitz, Cornelis Punt, Eduard Diaz Rubio, Miriam Koopman, Chiara Cremolini, Volker Heinemann, Christophe Tournigard, Carsten Bokemeyer, Charles Fuchs, Niall Tebbutt, John Souglakos, Jean-Yves Doulliard, Fairooz Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Qian Shi, Axel Grothey, Richard Adams
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Benchmarking international cancer survival differences is necessary to evaluate and improve healthcare systems. Our aim was to assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) p
Externí odkaz:
https://doaj.org/article/bf4aa20a3f6a47ca83257f0396cc016f
Autor:
Jan Franko, Jun Yin, Richard A. Adams, John Zalcberg, Jack Fiskum, Eric Van Cutsem, Richard M. Goldberg, Herbert Hurwitz, Carsten Bokemeyer, Fairooz Kabbinavar, Alexandra Curtis, Jeffery Meyers, Benoist Chibaudel, Takayuki Yoshino, Aimery de Gramont, Qian Shi
Publikováno v:
European Journal of Cancer. 174:142-152
Higher body mass index is associated with a higher incidence of colorectal cancer (CRC) but also with improved survival in metastatic CRC (mCRC). Whether weight change after mCRC diagnosis is associated with survival remains largely unknown.We analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b9f27e4dcc457dfef67093938ab81
https://doi.org/10.1016/j.ejca.2022.07.021
https://doi.org/10.1016/j.ejca.2022.07.021
Autor:
Mark J. Ratain, Yusuke Nakamura, Hedy L. Kindler, Richard L. Schilsky, Richard M. Goldberg, Howard L. McLeod, Kathleen M. Giacomini, Herbert Hurwitz, Dylan Glubb, Liewei Wang, Paula Friedman, Liang Li, Taisei Mushiroda, Donna Hollis, Chen Jiang, Hitoshi Zembutsu, Michiaki Kubo, Patrick Evans, Nancy L. Cox, Kouros Owzar, Federico Innocenti
Background and Aims: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ce98ab8b3e0104ecb8784e40133b2f
https://doi.org/10.1158/1078-0432.c.6520257.v1
https://doi.org/10.1158/1078-0432.c.6520257.v1
Autor:
Mark J. Ratain, Yusuke Nakamura, Hedy L. Kindler, Richard L. Schilsky, Richard M. Goldberg, Howard L. McLeod, Kathleen M. Giacomini, Herbert Hurwitz, Dylan Glubb, Liewei Wang, Paula Friedman, Liang Li, Taisei Mushiroda, Donna Hollis, Chen Jiang, Hitoshi Zembutsu, Michiaki Kubo, Patrick Evans, Nancy L. Cox, Kouros Owzar, Federico Innocenti
PDF file - 155K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd7a0bf31a75d38f507299f7efbc59b
https://doi.org/10.1158/1078-0432.22444674
https://doi.org/10.1158/1078-0432.22444674
Autor:
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L. Reckamp, Sunil Sharma, Hirak Der-Torossian, James G. Christensen, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Richard Chao, Geoffrey I. Shapiro
Publikováno v:
Targeted oncology.
Heightened signaling by mesenchymal epithelial transition factor (MET) is implicated in tumorigenesis. Glesatinib is an investigational, oral inhibitor of MET and AXL.This phase I study determined the maximum tolerated dose (MTD), recommended phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99acbb155cc20d52f385b59aa3aaa996
https://pubmed.ncbi.nlm.nih.gov/36459255
https://pubmed.ncbi.nlm.nih.gov/36459255
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc05d5f5ceb67f6daf199012f338e4cb
https://doi.org/10.1158/1078-0432.ccr-19-1209
https://doi.org/10.1158/1078-0432.ccr-19-1209
Autor:
Einat S Shmueli, Morteza Raeisi, Benoist Chibaudel, Herbert Hurwitz, Leonard B. Saltz, Fairooz F. Kabbinavar, Niall C. Tebbutt, Axel Grothey, Richard Adams, John Raymond Zalcberg, Takayuki Yoshino, Jean-Baptiste Bachet, Romain Cohen, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont
Publikováno v:
Journal of Clinical Oncology. 41:118-118
118 Background: Anti-VEGF is widely used in the treatment (trt) of metastatic colorectal cancer (mCRC). Only studies with bevacizumab (BEV) have shown survival benefit (bnf) in first line trt. The magnitude of bnf might differ based on the metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::075bf270d5824f640b34b522fbdddd7c
https://doi.org/10.1200/jco.2023.41.4_suppl.118
https://doi.org/10.1200/jco.2023.41.4_suppl.118
Autor:
Ace J. Hatch, Christel Rushing, Emily Bolch, Hope E. Uronis, S. David Hsu, James Leroy Wells, Abigail B. McLeod, Donna Niedzwiecki, Christy Arrowood, Kimberly L. Blackwell, John H. Strickler, P. Kelly Marcom, S. Yousuf Zafar, Michael A. Morse, Herbert Hurwitz, Ivy Altomare, Sherri Haley, Andrew B. Nixon, Fatima A. Rangwala, David Z. Chang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544ae352d7f5233576a777ba7b6f4aa4
http://link.springer.com/article/10.1186/s12885-019-6234-8
http://link.springer.com/article/10.1186/s12885-019-6234-8
Autor:
Sunil Sharma, Pierre Jordaan, Herbert Hurwitz, Shodeinde Coker, Lionel D. Lewis, Juan Pablo Zarate, Ding Wang
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:383-392
To evaluate the effect of lapatinib on the QTc interval and ECG parameters in patients with advanced solid tumors. This was a multicenter, placebo-controlled study in subjects with advanced solid tumors. Subjects were administered two doses of matchi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18855179bf1e1a50bd321e69aac7964a
https://doi.org/10.1007/s00280-019-03880-9
https://doi.org/10.1007/s00280-019-03880-9
Autor:
Howard A. Burris, Vaikunth Cuchelkar, Marwan Fakih, Steven Blotner, Ron Bose, Alyssa Stone, Kanwal Pratap Singh Raghav, Razelle Kurzrock, Katja Schulze, David R. Spigel, Mary Beattie, John D. Hainsworth, Herbert Hurwitz, Christopher Sweeney, Robert R. McWilliams, Ari M. Vanderwalde, Charles Swanton, Funda Meric-Bernstam
Publikováno v:
The Lancet Oncology. 20:518-530
Summary Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b1b2b6a775bf4978e6e76bccb49aae
https://doi.org/10.1016/s1470-2045(18)30904-5
https://doi.org/10.1016/s1470-2045(18)30904-5